not an expert statistics person , but I’ve posted a link before that explains futility analysis.
—- as I understand it a statistician has some sort of calculation that spits out a probability (of success / failure) for the final endpoint based on what ever is seen at interim in first few patients , in this case proteinuria difference.
—- it’s normally for the company to decide what is the lowest probability they’ll accept before deciding if it’s futile or not to keep trial going.
—- this will only apply to proteinurya endpoint not gfr as the futility in March appears to be on protein only
—-/ despite some other posters claims this has absolutely zilch to do with p value in the usual sense
Ann: Application for quotation of securities - DXB, page-95
-
- There are more pages in this discussion • 59 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
61.0¢ |
Change
0.055(9.91%) |
Mkt cap ! $335.3M | |||
| Open | High | Low | Value | Volume |
| 57.0¢ | 61.5¢ | 56.5¢ | $1.938M | 3.305M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3652 | 60.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 61.0¢ | 27035 | 1 |
View Market Depth
| Last trade - 16.10pm 20/06/2024 (20 minute delay) ? |
| DXB (ASX) Chart |